Sandeep Gurbuxani to Proteasome Inhibitors
This is a "connection" page, showing publications Sandeep Gurbuxani has written about Proteasome Inhibitors.
Connection Strength
0.052
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.052